RCS - LungLife AI, INC - Presentation at NCI's EDRN Meeting

LungLife AIAnnouncement

17/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240417:nRSQ8548Ka&default-theme=true

RNS Number : 8548K  LungLife AI, INC  17 April 2024

LungLife AI, Inc.

(the "Company" or "LungLife")

 

LungLife to present at US National Cancer Institute's Early Detection Research
Network Meeting

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the
early detection of lung cancer, announces it has been invited to present at
the National Cancer Institute's ("NCI") Early Detection Research Network
("EDRN") meeting in Tempe, Arizona on 17 April 2024.

 

The EDRN is a division of the United States NCI, the federal government's
principal agency for cancer research and training, which works collaboratively
amongst its members to bring new diagnostic biomarkers to clinical use.

 

In October 2022
(https://investors.lunglifeai.com/lunglife-to-participate-in-the-us-national-cancer-institutes-early-detection-research-network/)
, LungLife was selected to participate in the Lung Cancer Biomarker
Development Laboratory of the EDRN, combining LungLB® with imaging to assist
early detection research, as well as validate combined test performance in
patients with indeterminate lung nodules.

 

In this meeting, LungLife will present the LungLB® test, including results
from the validation study and information on the Early Access Program, and
describe its role in the ongoing EDRN study for indeterminate lung nodules to
a group of over 300 investigators from the NCI, academic institutions and
industry focused on early cancer detection.

 

Paul Pagano, CEO of LungLife AI, said "We are excited that through our ongoing
EDRN partnership we have the opportunity to present at this meeting to
collaborators and potential end users of LungLB®.

 

"The work of the EDRN closely aligns with LungLife's mission to drive the
early detection of lung cancer and will provide further clinical evidence for
the LungLB® technology as well as widen awareness of our technology with
leading US investigators and diagnostics industry partners."

 

For further information please contact:

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                                   Tel: +44 (0) 20 3841 6208

 Tom Nicholson / Cameron Duncan

 Walbrook PR Limited                                        Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                           (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings / Phillip Marriage          Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

About Lung Cancer

Lung cancer is the most fatal form of cancer worldwide and early detection is
critical to achieve better outcomes. Early detection involves the evaluation
of indeterminate lung nodules, of which there are over 1.5M identified by CT
scan each year in the United States alone. Evaluation often involves
significant unnecessary invasive procedures such as biopsy for patients with
benign nodules and long delays in potentially curative treatment for patients
with cancerous nodules that are selected for monitoring via non-invasive
imaging. LungLB® is intended to help with earlier diagnosis in the evaluation
process.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAIFMATMTTBBJI